The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma

Carcinogenesis

Volumn 32, Issue 11, 2011, Pages 1713-1723

  Doberstein, Kai ^a   Pfeilschifter, Josef ^a   Gutwein, Paul ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; NERVE CELL ADHESION MOLECULE L1; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR SLUG; UVOMORULIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; BLOTTING, WESTERN; CADHERINS; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DOWN-REGULATION; ELAFIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY; KIDNEY NEOPLASMS; MEMBRANE PROTEINS; NEURAL CELL ADHESION MOLECULE L1; PAX2 TRANSCRIPTION FACTOR; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 80755187822     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr195     Document Type: Article

References (58)

1. Berrino, F. (2003) The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies. Ann. Oncol., 14 (suppl. 5), v9-v13.
2. Gupta, K. et al. (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev., 34, 193-205.
3. Ozcan, A. et al. (2009) PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am. J. Clin. Pathol., 131, 393-404.
4. Luu, V.D. et al. (2009) Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin. Cancer Res., 15, 3297-3304.
5. Daniel, L. et al. (2001) Pax-2 expression in adult renal tumors. Hum. Pathol., 32, 282-287.
6. Ostrom, L. et al. (2000) Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev. Biol., 219, 250-258.
7. Gnarra, J.R. et al. (1995) Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res., 55, 4092-4098.
8. Dressler, G.R. et al. (1993) Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature, 362, 65-67.
9. Dressler, G.R. et al. (1990) Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system. Development, 109, 787-795.
10. Clark, P. et al. (2004) Rescue of defective branching nephrogenesis in renalcoloboma syndrome by the caspase inhibitor, Z-VAD-fmk. J. Am. Soc. Nephrol., 15, 299-305.
11. Robson, E.J. et al. (2006) A PANorama of PAX genes in cancer and development. Nat. Rev. Cancer, 6, 52-62.
12. Mazal, P.R. et al. (2005) Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod. Pathol., 18, 535-540.
13. Memeo, L. et al. (2007) Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am. J. Clin. Pathol., 127, 225-229.
14. Buttiglieri, S. et al. (2004) Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J. Biol. Chem., 279, 4136-4143.
15. Torban, E. et al. (2000) PAX2 suppresses apoptosis in renal collecting duct cells. Am. J. Pathol., 157, 833-842.
16. Tamimi, Y. et al. (2008) WNT5A is regulated by PAX2 and may be involved in blastemal predominantWilms tumorigenesis. Neoplasia, 10, 1470-1480.
17. Wu, H. et al. (2005) Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature, 438, 981-987.
18. Hurtado, A. et al. (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature, 456, 663-666.
19. Stuart, E.T. et al. (1995) Loss of p53 function through PAX-mediated transcriptional repression. EMBO J., 14, 5638-5645.
20. Hewitt, S.M. et al. (1997) Transcriptional activation of the bcl-2 apoptosis suppressor gene by the paired box transcription factor PAX8. Anticancer Res., 17, 3211-3215.
21. Gutwein, P. et al. (2009) Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur. J. Cancer, 45, 478-489.
22. Allory, Y. et al. (2005) The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin. Cancer Res., 11, 1190-1197.
23. Schelter, F. et al. (2010) A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J. Biol. Chem., 285, 26335-26340.
24. Gutwein, P. et al. (2003) ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J., 17, 292-294.
25. Schreiber, E. et al. (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res., 17, 6419.
26. Ludwig, A. et al. (2005) Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb. Chem. High Throughput Screen., 8, 161-171.
27. Gutwein, P. et al. (2010) ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases. J. Biomed. Sci., 17, 3.
28. Ungerer, C. et al. (2010) ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma. Biochem. Biophys. Res. Commun, 401, 363-369.
29. Elbashir, S.M. et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
30. Mechtersheimer, S. et al. (2001) Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J. Cell Biol., 155, 661-673.
31. Lee, S.B. et al. (2010) ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J. Invest. Dermatol., 130, 763-773.
32. Reiss, K. et al. (2009) The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin. Cell Dev. Biol., 20, 126-137.
33. Murphy, G. (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer, 8, 929-941.
34. Onder, T.T. et al. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res., 68, 3645-3654.
35. Gutwein, P. et al. (2005) Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin. Cancer Res., 11, 2492-2501.
36. Cohen, H.T. et al. (2005) Renal-cell carcinoma. N. Engl. J. Med., 353, 2477-2490.
37. Mochizuki, S. et al. (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci., 98, 621-628.
38. Doberstein, K. et al. (2010) L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis, 32, 262-270.
39. Gavert, N. et al. (2007) Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res., 67, 7703-7712.
40. Gavert, N. et al. (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol., 168, 633-642.
41. Birchmeier, C. et al. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 4, 915-925.
42. Jiang, W. et al. (1999) Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol., 29, 209-248.
43. Kaelin, W.G.Jr. (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer, 2, 673-682.
44. Linehan, W.M. (2008) Kidney cancer: opportunity for disease specific targeted therapy. Urol. Oncol., 26, 542.
45. Shibamoto, S. et al. (1994) Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes. Commun., 1, 295-305.
46. Herynk, M.H. et al. (2003) Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin. Exp. Metastasis, 20, 291-300.
47. Nagafuchi, A. et al. (1987) Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature, 329, 341-343.
48. Gumbiner, B.M. (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell Biol., 6, 622-634.
49. Le Gall, S.M. et al. (2009) ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol. Biol. Cell, 20, 1785-1794.
50. Gaida, M.M. et al. (2010) Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int. J. Mol. Med., 26, 281-288.
51. Oh, S.T. et al. (2009) The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas. J. Cutan. Pathol., 36, 395-401.
52. Epstein, J. et al. (1994) Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes. J. Biol. Chem., 269, 8355-8361.
53. Prinzen, C. et al. (2005) Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J., 19, 1522-1524.
54. Stayner, C. et al. (2006) Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease. Hum. Mol. Genet., 15, 3520-3528.
55. Winyard, P.J. et al. (1996) The PAX2 tanscription factor is expressed in cystic and hyperproliferative dysplastic epithelia in human kidney malformations. J. Clin. Invest., 98, 451-459.
56. Friedli, A. et al. (2009) The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int. J. Biochem. Cell Biol., 41, 1572-1580.
57. Stoeck, A. et al. (2007) L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol., 104, 461-469.
58. Sebens Muerkoster, S. et al. (2009) Alpha5-integrin is crucial for L1CAMmediated chemoresistance in pancreatic adenocarcinoma. Int. J. Oncol., 34, 243-253.